Structural biology (SB) provides a critical drug discovery and development tool for accurately identifying and understanding the structure of a target. Alessandro Piai, PhD, Principal Research Scientist at IRBM, describes the company’s expertise in nuclear magnetic resonance (NMR) and how it can be leveraged to accelerate the identification of molecules for progression to the clinic.
Interview with Piero Di Lorenzo
The Italian company: “Vaccine, we’re ready for clinical trial with Oxford”
An adenovirus, the common cold virus, as carrier. The coronavirus surface antigens as the engine able to trigger the immune response. Here’re the invisible ingredients of the Anglo-Italian vaccine. Clinical trials should start on 550 healthy volunteers in England by the end of April. “We aim to make the first doses available in September”, Piero Di Lorenzo, President and CEO of IRBM, says. IRBM is the Italian company currently committed to testing. During the interview, Di Lorenzo explains the importance of the partnership between the Jenner Institute of Oxford University and Advent, the cGMP-certified Contract Development and Manufacturing Organization of IRBM Group. He also clarifies how the vaccine is produced and which waiting time we should expect, both in terms of large-scale manufacture and approval process.
Article by Federico Mereta published on Il Secolo XIX – 14/04/2020